Quantcast
Last updated on April 17, 2014 at 10:14 EDT

Latest Bioterrorism Stories

2014-03-05 08:20:33

Hawaii Biotech Receives DoD Contract to Develop Anti-Botulism Drug HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed...

2014-02-20 12:00:18

A Kansas State University epidemiologist is helping cats, pet owners and soldiers stay healthy by studying feline tularemia and the factors that influence its prevalence. Ram Raghavan, assistant professor of diagnostic medicine and pathobiology, and collaborative researchers have found that a certain combination of climate, physical environment and socio-ecologic conditions are behind tularemia infections among cats in the region. More than 50 percent of all tularemia cases in the U.S....

2014-02-14 08:25:55

Soligenix Initiates Medical Countermeasure Development of SGX943 PRINCETON, N.J., Feb. 14, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has...

2014-02-04 12:28:56

HONOLULU, Feb. 4, 2014 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc. a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through Q1 2014, valued at $1.1 million. The grant for the full five-year period equals $7.4 million. Under...

2013-12-17 12:25:45

WASHINGTON, Dec. 17, 2013 /PRNewswire-USNewswire/ -- A report released today by Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF) finds the nation's ability to prevent and control infectious disease outbreaks are hampered by outdated systems and limited resources. (Logo: http://photos.prnewswire.com/prnh/20100204/TFAHLOGO) The Outbreaks: Protecting Americans from Infectious Diseases report finds that a majority of states (34) score 5 or lower out of 10 key...

2013-11-15 08:27:52

Order completion results from a successful collaboration between Bavarian Nordic and the U.S. government that has continued for more than a decade KVISTGAARD, Denmark, November 15, 2013 /PRNewswire/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that it completed the delivery of 20 million doses of IMVAMUNE(R) smallpox vaccine to the U.S. Strategic National Stockpile (SNS) for use in the event of a smallpox emergency in the U.S. This order completion is the result of...

2013-10-31 08:32:49

PRINCETON, N.J., Oct. 31, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) where there remains an unmet medical need, announced today submission of a full contract proposal to the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases. Successful...

2013-10-17 08:29:01

PRINCETON, N.J., Oct. 17, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today the formation of an international melioidosis Scientific Advisory Board (SAB). Comprised of clinicians and researchers from Australia, Thailand, Lao and The Netherlands with...

2013-06-10 08:29:34

NEWARK, Del., June 10, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that its patent covering the composition and production of a human monoclonal antibody for the treatment of anthrax infection has been allowed in China. This patent, which will issue from Chinese patent application No.:200680036136.1, is entitled "COMPOSITIONS AND METHODS FOR PRODUCTION OF IMMUNOGLOBULINS." (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) The claims of the allowed patent...

2013-05-20 16:25:43

Rapid, inexpensive test is promising for use in the field and in the lab, study results are published in PLOS ONE MOUNTAIN VIEW, Calif., May 20, 2013 /PRNewswire-iReach/ -- Specific Technologies, today announced the publication of results of the first study demonstrating detection of pathogenic bacteria, including potential bioterrorism agents such as Yersinia pestis and Bacillus anthracis which feature on the Center for Disease Control and Prevention's list of potential bio-threats....